Amarin (AMRN) Gives Back Some of Yesterday's 95% Gains
Tweet
Share
E-mailGet Alerts AMRN Hot Sheet
Up)Join SI Premium – FREE
After gaining 95 percent Monday on positive trial news, shares of Amarin Corporation plc (Nasdaq: AMRN) are down 2.75 percent in pre-open trading today as some investors lock in gains.
Amarin announced statistically significant top-line results from its ANCHOR trial for the Company's lead product candidate, AMR101. The Phase 3 trial met its primary and secondary efficacy endpoints for both the 4 gram and 2 gram daily doses.
Amarin said triglyceride levels decreased 21.5% and 10.1% from baseline versus placebo at 4 gram and 2 gram doses, respectively - LDL-C decreased at both doses within the predefined non-inferiority b.
Amarin announced statistically significant top-line results from its ANCHOR trial for the Company's lead product candidate, AMR101. The Phase 3 trial met its primary and secondary efficacy endpoints for both the 4 gram and 2 gram daily doses.
Amarin said triglyceride levels decreased 21.5% and 10.1% from baseline versus placebo at 4 gram and 2 gram doses, respectively - LDL-C decreased at both doses within the predefined non-inferiority b.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Super Micro Computer (SMCI) Falls 6%
- Tiziana Life Sciences (TLSA) Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today
- Alvotech (ALVO) signs U.S. agreement to expand access for adalimumab
Create E-mail Alert Related Categories
FDA, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
